WEBULL

Will Recent Share Buybacks Reshape Abbott’s (ABT) Capital Allocation Story?

Simply Wall St · 11/08/2025 23:25
  • Abbott Laboratories recently completed two share buyback programs, repurchasing a total of 45.9 million shares for US$5 billion under a 2021 announcement and 76,003 shares for US$9.48 million under a 2024 announcement, as disclosed in past reports.
  • These buybacks highlight Abbott’s ongoing efforts to return capital to shareholders, reflecting continued management confidence in the company’s long-term strategy despite recent mixed earnings results.
  • We’ll examine how Abbott’s recent buybacks, paired with its reaffirmed 2025 outlook, might influence its future investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 35 best rare earth metal stocks of the very few that mine this essential strategic resource.

Abbott Laboratories Investment Narrative Recap

To be a shareholder in Abbott Laboratories, you need confidence in its ability to deliver steady revenue growth and margin expansion driven by innovation in diagnostics, medical devices, and emerging markets, while navigating challenges in diagnostics and pricing power. The latest buyback news is a constructive sign but does not materially alter the near-term catalyst, sustained adoption of next-gen devices, or address the primary risk of ongoing pricing pressure in diagnostics, especially from heightened competition and Chinese procurement policies.

Most relevant to this buyback update is Abbott's October reaffirmation of its full-year 2025 organic sales growth and earnings guidance, despite headwinds in diagnostics and mixed quarterly results. This supports the case that capital returns, such as buybacks and a stable dividend, continue to run alongside efforts to strengthen core earnings, which is critical for investor sentiment as the company manages margin risk and the impact of external market shifts.

By contrast, a key issue investors should watch is whether extended pricing pressure in diagnostics could cut deeper into overall revenue growth than expected, especially if...

Read the full narrative on Abbott Laboratories (it's free!)

Abbott Laboratories' narrative projects $53.3 billion revenue and $9.4 billion earnings by 2028. This requires 7.3% yearly revenue growth and a $4.5 billion decrease in earnings from $13.9 billion.

Uncover how Abbott Laboratories' forecasts yield a $144.47 fair value, a 14% upside to its current price.

Exploring Other Perspectives

ABT Community Fair Values as at Nov 2025
ABT Community Fair Values as at Nov 2025

The Simply Wall St Community offers 10 fair value estimates for Abbott ranging widely from US$93.39 to US$144.47 per share. As pricing pressure in diagnostics remains a central concern for the company, these varied perspectives highlight how differently you and other market watchers might size up future risks.

Explore 10 other fair value estimates on Abbott Laboratories - why the stock might be worth 26% less than the current price!

Build Your Own Abbott Laboratories Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Seeking Other Investments?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.